Faes Farma, S.A.

BME:FAE Stok Raporu

Piyasa değeri: €1.1b

Faes Farma Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 5/6

Faes Farma has been growing earnings at an average annual rate of 8.3%, while the Pharmaceuticals industry saw earnings growing at 13.1% annually. Revenues have been growing at an average rate of 5.4% per year. Faes Farma's return on equity is 14.2%, and it has net margins of 19.4%.

Anahtar bilgiler

8.3%

Kazanç büyüme oranı

5.9%

EPS büyüme oranı

Pharmaceuticals Sektör Büyümesi5.0%
Gelir büyüme oranı5.4%
Özkaynak getirisi14.2%
Net Marj19.4%
Son Kazanç Güncellemesi30 Sep 2024

Yakın geçmiş performans güncellemeleri

Recent updates

Faes Farma, S.A. (BME:FAE) Just Released Its Third-Quarter Results And Analysts Are Updating Their Estimates

Nov 03
Faes Farma, S.A. (BME:FAE) Just Released Its Third-Quarter Results And Analysts Are Updating Their Estimates

Faes Farma, S.A. (BME:FAE) Just Released Its Full-Year Earnings: Here's What Analysts Think

Mar 01
Faes Farma, S.A. (BME:FAE) Just Released Its Full-Year Earnings: Here's What Analysts Think

Faes Farma (BME:FAE) Is Due To Pay A Dividend Of €0.0316

Dec 18
Faes Farma (BME:FAE) Is Due To Pay A Dividend Of €0.0316

Faes Farma (BME:FAE) Will Pay A Dividend Of €0.0316

Dec 04
Faes Farma (BME:FAE) Will Pay A Dividend Of €0.0316

Does Faes Farma (BME:FAE) Have A Healthy Balance Sheet?

Nov 24
Does Faes Farma (BME:FAE) Have A Healthy Balance Sheet?

Here's Why Faes Farma (BME:FAE) Can Manage Its Debt Responsibly

May 03
Here's Why Faes Farma (BME:FAE) Can Manage Its Debt Responsibly

Is There An Opportunity With Faes Farma, S.A.'s (BME:FAE) 50% Undervaluation?

Sep 21
Is There An Opportunity With Faes Farma, S.A.'s (BME:FAE) 50% Undervaluation?

Is Faes Farma (BME:FAE) A Risky Investment?

Aug 03
Is Faes Farma (BME:FAE) A Risky Investment?

Faes Farma (BME:FAE) Ticks All The Boxes When It Comes To Earnings Growth

Jun 17
Faes Farma (BME:FAE) Ticks All The Boxes When It Comes To Earnings Growth

Is Faes Farma (BME:FAE) Using Too Much Debt?

Mar 27
Is Faes Farma (BME:FAE) Using Too Much Debt?

Faes Farma (BME:FAE) Is Increasing Its Dividend To €0.14

Dec 13
Faes Farma (BME:FAE) Is Increasing Its Dividend To €0.14

Faes Farma's (BME:FAE) Dividend Will Be Increased To €0.17

Nov 29
Faes Farma's (BME:FAE) Dividend Will Be Increased To €0.17

Is Faes Farma (BME:FAE) A Risky Investment?

Sep 21
Is Faes Farma (BME:FAE) A Risky Investment?

Faes Farma, S.A. (BME:FAE) Interim Results: Here's What Analysts Are Forecasting For This Year

Jul 31
Faes Farma, S.A. (BME:FAE) Interim Results: Here's What Analysts Are Forecasting For This Year

Is Faes Farma (BME:FAE) Using Too Much Debt?

May 01
Is Faes Farma (BME:FAE) Using Too Much Debt?

Estimating The Fair Value Of Faes Farma, S.A. (BME:FAE)

Apr 07
Estimating The Fair Value Of Faes Farma, S.A. (BME:FAE)

Does Faes Farma, S.A. (BME:FAE) Have A Place In Your Dividend Portfolio?

Mar 22
Does Faes Farma, S.A. (BME:FAE) Have A Place In Your Dividend Portfolio?

Faes Farma's (BME:FAE) Solid Earnings May Rest On Weak Foundations

Mar 06
Faes Farma's (BME:FAE) Solid Earnings May Rest On Weak Foundations

Faes Farma (BME:FAE) Has Compensated Shareholders With A Respectable 61% Return On Their Investment

Feb 22
Faes Farma (BME:FAE) Has Compensated Shareholders With A Respectable 61% Return On Their Investment

I Ran A Stock Scan For Earnings Growth And Faes Farma (BME:FAE) Passed With Ease

Jan 16
I Ran A Stock Scan For Earnings Growth And Faes Farma (BME:FAE) Passed With Ease

Faes Farma (BME:FAE) Seems To Use Debt Rather Sparingly

Dec 08
Faes Farma (BME:FAE) Seems To Use Debt Rather Sparingly

Gelir ve Gider Dağılımı

Faes Farma nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

BME:FAE Gelir, gider ve kazançlar (EUR Millions )
TarihGelirKazançlarG+A GiderleriAr-Ge Giderleri
30 Sep 24504981310
30 Jun 24494971260
31 Mar 24482951230
31 Dec 23473921220
30 Sep 2347290980
30 Jun 23469901200
31 Mar 2346791960
31 Dec 22462891160
30 Sep 22460861130
30 Jun 2246688910
31 Mar 22449881110
31 Dec 2142982870
30 Sep 21416811070
30 Jun 21398741060
31 Mar 21394731040
31 Dec 20411731050
30 Sep 2040877920
30 Jun 20407731060
31 Mar 20409681060
31 Dec 19383641040
30 Sep 19379601140
30 Jun 1936359970
31 Mar 1935154950
31 Dec 1834052940
30 Sep 1833451870
30 Jun 1833049860
31 Mar 1830847810
31 Dec 1728241770
30 Sep 1726639700
30 Jun 1725039670
31 Mar 1724138660
31 Dec 1623737660
30 Sep 1622635640
30 Jun 1622234630
31 Mar 1622032620
31 Dec 1521430610
30 Sep 1520728591
30 Jun 1520327580
31 Mar 1519626450
31 Dec 1419825580
30 Sep 1419523601
30 Jun 1419424601
31 Mar 1419220601
31 Dec 1319323601

Kaliteli Kazançlar: FAE has high quality earnings.

Büyüyen Kar Marjı: FAE's current net profit margins (19.4%) are higher than last year (19%).

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: FAE's earnings have grown by 8.3% per year over the past 5 years.

Büyüme Hızlandırma: FAE's earnings growth over the past year (8.8%) exceeds its 5-year average (8.3% per year).

Kazançlar vs. Sektör: FAE earnings growth over the past year (8.8%) exceeded the Pharmaceuticals industry 4.5%.

Özkaynak Getirisi

Yüksek ROE: FAE's Return on Equity (14.2%) is considered low.

Varlık Getirisi

Kullanılan Sermaye Getirisi

Geçmişte güçlü performans gösteren şirketleri keşfedin

7D

1Y

7D

1Y

7D

1Y